Paclitaxel-Induced Peripheral Neuropathy Using NCI-CTCin Isfahan, Iran Paclitaxel-induced peripheral neuropathy
Iranian Journal of Pharmaceutical Sciences,
Vol. 4 No. 3 (2008),
1 Tir 2008
,
Page 189-192
https://doi.org/10.22037/ijps.v4.41117
Abstract
Paclitaxel is a highly effective anticancer agent. It is active against a broad range of cancers that are generally considered refractory to conventional chemotherapy.Paclitaxel induces a peripheral neuropathy (PN) that is characterized by sensory symptoms such as numbness and paresthesia in a glove and stocking distribution.PN may be severe and dose limiting at initial doses above 275 mg/m2. Our purpose was to evaluate the incidence, severity, dose dependency, and reversibility of paclitaxel-induced neuropathy. We studied 45 patients with breast cancer, treated with Paclitaxel (240, 270, 300 mg/m2) in an average of 4 cycles of treatment.Paclitaxel was administered by a 3 h intravenous infusion every 3 weeks in all patients.We used National Cancer Institute-Common Toxicity Criteria (NCI-CTC) to evaluate peripheral neuropathy. The cumulative dose of paclitaxel in each patient was also measured. The severity of symptoms was graded. Incidence and reversibility of neuropathy was measured in an interview with the patient. Paresthesias appeared in 39 (86.6%) patients after an average cumulative dose of 394 mg/m2.In most patients, PN was seen after the first or second dose (68%) of paclitaxel and then stabilized in 36%, improved in 36%, resolved completely in 24% and progressed in 4%. There was no need to discontinue Paclitaxel in any of the patients due to PN.In view of our experience in the present study, we found that Paclitaxel-induced neuropathy is a dose-dependent phenomenon, and most of the symptoms occurred after the first or second phase of treatment.
- Breast cancer
- Chemotherapy
- Paclitaxel
- Peripheral neuropathy.
How to Cite
References
[2]Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induce neuropathy.Ann Oncol1995; 6: 489-94.
[3]Implications of taxane-induced neuropathy (http://www.cbcrp.org/research/page Grant.asp?Grant id=3795 accessed 11 Jun, 2007).
[4]Bárdos G, Móricz K, Jaszlits L, Rabloczky G,Tory K, Rácz I, Bernáth S, Sümegi B, Farkas B,Literáti-Nagy B, Literáti-Nagy P. BGP-15, a hydroximic acid derivative, protects against cisplatin or taxol induced peripheral neuropathy in rats. Toxicol Appl Pharm2003; 190: 9-16.
[5]Schiff PB, Horowitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci1980; 77: 1561-5.
[6]Iniguez C, Larrode P, Mayordomo JI, Gonzales P, Adelatado S ,Yubcro A, Tres A, Morales F.Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel.Neurology1998; 51: 868-70.
[7]Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, De Angelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. Neuro-Oncology 1997; 35: 47-53.[8]National Cancer Institute-Cancer Therapy Evaluation Program. Common toxicity criteria.Version 2 April 30 1999 (http: //ctep.info.nih.gov)
[9]Pignata S, DePlacido S, Biamonte R, Scambia G,DiVagno G, Colucci G, Febbraro A, Marinaccio M, Manzione L, Carteni G, Nardi M, Danese S,Massidda D, Perrone F. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel the multicenter Italian Trial in ovarian cancer (MITO)-4) Retrospective study. BMC Cancer2006; 6: 5.
[10]Trimble EL, Adams JD, Vena D. Paclitaxel for platinum refractory ovarian cancer: Result from the first 1000 patients registered to National Cancer Treatment Referral center 9103. J ClinOncol1993; 11: 2405-10.[11]Thigpen JT, Blessing JI, Ball, Hummel SJ, Barrett RY. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: Gynecological oncology group study. J Clin Oncol1994; 12: 1748-53.
[12]Rowinsky EK, Donehower RC. Paclitaxel (Taxol).N Engl J Med 1995; 333: 75.
[13]Arqvriou AA, Chroni E, Koutras A, Ellul J,Papapetropulos S, Katsoulas G, Iconomon G,Kalofonos HP. Vitamin E for prophylaxis against chemotherapy-induce neuropathy: A randomized controlled trial. Neurology2005; 64: 26-31.
[14]Arqvriou AA, Chroni E, Koutras A, Iconomou G,Papapetropouloss, Polychronopoulos P.Preventing paclitaxel-induce neuropathy: A phase II trial of vitamin E supplementation. J PainSymptom Manag2006; 32: 237-44.
[15]De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy a short review. CNS Drugs2007; 21 S1: 39-43.
[16]Ghirardi O, Vertechy M, Vesci L, Centa A,Nicolini G, Galbiati S, Ciogli C, Quattrini G,Pisano C, Cundari S, Rigamonti LM.Chemotherapy-induced allodinia: Neuroprotective effect of acety-L-carnitine. In vivo2005; 19: 631-7.
- Abstract Viewed: 297 times
- IJPS_Volume 4_Issue 3_Pages 189-192 Downloaded: 198 times